1. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998;59:288-294.

2. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003;361: 1801-1809.

3. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2006:CD003429.

4. Astermark J, Petrini P, Tengborn L, et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999;105:1109-1113.

5. Berntorp E. Prophylactic therapy for haemophilia: Early experience. Haemophilia 2003; 9(Suppl 1):5-9; discussion 9.

6. Blanchette VS, Manco-Johnson M, Santagostino E, et al. Optimizing factor prophylaxis for the haemophilia population: Where do we stand? Haemophilia 2004;10(Suppl 4):97-104.

7. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting factor Concentrate to Prevent Bleeding). MASAC Document #179. National Hemophilia Foundation 2007; 116 West 32nd Street, New York, NY 10001.

8. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-544.

9. Fiebig EW, Busch MP. Emerging infections in transfusion medicine. Clin Lab Med 2004;24:797-823.

10. Srivastava A. Optimizing clotting factor replacement therapy in hemophilia: A global need. Hematology 2005;10(Suppl 1):229-230.

11. MASAC Recommendations Concerning the Treatment of Hemophilia and Other Bleeding Disorders. MASAC Document #182. National Hemophilia Foundation 2008; 11ó West 32nd Street, New York, NY 10001.

12. Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med 2001;344:1773-1779.

13. Shord SS, Lindley CM. Coagulation products and their uses. Am J Health Syst Pharm 2000;57:1403-1417; quiz 1418-1420.

14. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987;ó9:454-459.

15. Werner EJ, Broxson EH, Tucker EL, et al. Prevalence of von Willebrand disease in children: A multiethnic study. J Pediatr 1993;123:893-898.

1ó. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (vWD): Evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008;14:171-232.

17. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004;351:ó83-ó94.

18. Friedman KD, Rodgers GM. Inherited coagulation disorders. In: Glader B, ed. Wintrobe's Clinical Hematology, Vol. 2. Philadelphia: Lippincott Williams and Wilkins, 2004:1ó19-1óó7.

19. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004;104:1243-1252.

20. Roberts HR, Escobar MA. Other clotting factor deficiencies. In: Hoffman R, Benz EJJ, Shattil SJ, eds. Hematology: Basic Principles and Practice. Philadelphia: Elsevier, 2005:2047-20ó9.

21. Okajima K, Sakamoto Y, Uchiba M. Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: A study of 204 cases. Am J Hematol 2000;ó5:215-222.

22. Levi M. Disseminated intravascular coagulation. Crit Care Med 2007;35:2191-2195.

23. Rodgers GM. Acquired coagulation disorders. In: Greer JP, Foerster J, Lukens JN, et al., eds. Wintrobe's Clinical Hematology, Vol. 2. Philadelphia: Lippincott Williams and Wilkins, 2004:1óó9.

24. Levi M. Disseminated intravascular coagulation: What's new? Crit Care Clin 2005;21:449-467.

25. BickRL. Disseminated intravascular coagulation: Pathophysiological mechanisms and manifestations. Semin Thromb Hemost 1998;24:3-18.

26. de Pont AC, Bakhtiari K, Hutten BA, et al. Recombinant human activated protein C resets thrombin generation in patients with severe sepsis—A case control study. Crit Care 2005;9:R490-R497.

27. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. Highdose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001;286:1869-1878.

28. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999;94:909-913.

29. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.

30. Medeiros D, Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura: Immediate response to therapy and long-term outcome. J Pe-diatr 1998;133:334-339.

31. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.

32. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-1584.

33. Sadler J, Poncz M. Antibody-mediated thrombotic disorders: Idiopathic thrombotic thrombocytopenic purpura and heparin-induced thrombocytopenia. In: Licht-man M, ed. Williams Hematology. New York: McGraw-Hill, 2006:2031-2054.

68 Sickle Cell Anemia

Tracy M. Hagemann and Teresa V. Lewis


Treating Rheumatoid Arthritis With Herbs Spices Roots

Treating Rheumatoid Arthritis With Herbs Spices Roots

Did You Know That Herbs and Spices Have Been Used to Treat Rheumatoid Arthritis Successfully for Thousands of Years Do you suffer with rheumatoid arthritis Would you like to know which herbs and spices naturally reduce inflammation and pain 'Treating Rheumatoid Arthritis with Herbs, Spices and Roots' is a short report which shows you where to start.

Get My Free Ebook

Post a comment